A Skin and Synovial Tissue Assessment of Overlapping Genes and Their Response After 3 Months Treatment With Apremilast in Patients With Psoriatic Arthritis

Trial Profile

A Skin and Synovial Tissue Assessment of Overlapping Genes and Their Response After 3 Months Treatment With Apremilast in Patients With Psoriatic Arthritis

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Apremilast (Primary)
  • Indications Psoriatic arthritis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 20 Oct 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2016.
    • 20 Oct 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2016.
    • 20 Oct 2016 Status changed from recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top